Last updated: February 21, 2026
What is NDC 71776-0100?
NDC 71776-0100 is a specific National Drug Code representing a medical product, typically a biologic or injectable. Based on available data, this NDC corresponds to Dexpramipexole, which is under investigation for various neurological indications.
Market Overview
The market for drugs like NDC 71776-0100 primarily targets neurological and neurodegenerative diseases, notably amyotrophic lateral sclerosis (ALS). The landscape is characterized by high unmet medical needs, limited approved treatments, and ongoing clinical trials.
Current Market Landscape
| Segment |
Details |
| Target Indications |
ALS, other neurodegenerative disorders |
| Market Size (2022) |
Estimated at around $500 million globally for ALS therapeutic space |
| Key Competitors |
Riluzole, Edaravone (Radicava), emerging agents like Tadekinig alfa, AMX0035 |
| Approval Status |
Pending or early-stage approval; some ingredients may still be in clinical trials |
Market Drivers
- Rising prevalence of ALS (approx. 2 per 100,000 globally)
- Increasing investment in neurodegenerative research
- Lack of curative treatments, creating high demand for novel agents
- Diagnostic advancements leading to earlier detection
Key Challenges
- Lengthy and costly clinical development phases
- Regulatory hurdles, particularly navigating FDA approval pathways
- Competitive landscape with established therapies
Pricing Landscape
Existing Neurological Drugs
| Drug Name |
Type |
US List Price (Approx.) |
Notes |
| Riluzole |
Oral, Small Molecule |
$8,000 – $12,000/year |
First approved for ALS in 1995 |
| Edaravone (Radicava) |
IV, Free Radical Scavenger |
$26,000 – $50,000/6-week cycle |
More recent approval for ALS in 2017 |
| AMX0035 (Relyvrio) |
Combination therapy |
~$100,000/year |
Approved in US, Canada, pending other regions |
Estimated Pricing for NDC 71776-0100
As a novel agent, pricing projections depend on:
- Mechanism of action: If it offers significant clinical benefits over existing options
- Regulatory approval: Faster pathways may influence initial pricing
- Market exclusivity: Patent protection or orphan drug status impact price points
Assuming NDC 71776-0100 advances toward approval with similar efficacy to existing therapies, initial list prices could reflect:
| Price Range |
Justification |
| $40,000 – $80,000/year |
Reflects premium pricing for potentially superior efficacy |
| $20,000 – $40,000/year |
More conservative, competitive pricing strategy |
Price Trend Projections
| Year |
Expected Price Range |
Key Factors |
| 2023 |
$40,000 – $70,000 |
Initial launch, tentative based on clinical data |
| 2024 |
$35,000 – $65,000 |
Competitive market adjustments, payer negotiations |
| 2025 |
$30,000 – $60,000 |
Market stabilization as more data becomes available |
Cost-Effectiveness
- The cost-effectiveness approach favors pricing aligned with clinical benefits
- Health technology assessments (HTAs) in key markets (e.g., NICE in the UK, ICER in the US) influence final pricing strategies
Revenue Projections
5-Year Revenue Estimate
| Year |
Estimated Units |
Revenue Range |
Assumptions |
| 2023 |
1,000 – 2,000 |
$40 million – $140 million |
Launch year, early adoption, limited patient pool |
| 2024 |
3,000 – 6,000 |
$105 million – $360 million |
Expansion into broader markets, increase in diagnosed patients |
| 2025 |
6,000 – 12,000 |
$180 million – $720 million |
Market penetration, ongoing clinical validation |
Regulatory and Competitive Factors
- Regulatory pathways like accelerated approval or orphan drug status reduce time to market and can impact pricing negatively or positively based on exclusivity and market control.
- Competitive pressures from existing therapies and pipeline entrants influence market share and pricing.
Key Takeaways
- The existing market for ALS drugs in the US and Europe is approximately $500 million.
- Initial pricing for NDC 71776-0100 is likely to start between $40,000 and $70,000 annually, depending on efficacy and approval status.
- Revenue projections indicate significant growth potential if clinical benefits are substantiated, with estimates reaching over $700 million annually by 2025.
- Market dynamics, regulatory pathways, and competitive landscape substantially influence pricing and sales volume.
FAQs
-
What factors influence the pricing of NDC 71776-0100?
Pricing depends on clinical efficacy, regulatory approval, market exclusivity, competition, and payer negotiations.
-
How does the ALS market influence potential revenue for NDC 71776-0100?
The ALS market’s limited treatment options and high unmet need create opportunities for high-margin sales, especially if clinical trials show significant benefits.
-
What is the typical timeline for a drug like NDC 71776-0100 to reach the market?
Clinical trials typically span 3-7 years, with regulatory review adding 1-2 years. Fast-track designations can accelerate approval.
-
Are there regulatory incentives for drugs targeting ALS?
Yes, orphan drug designation, breakthrough therapy, and accelerated approval pathways are available to expedite development and market entry.
-
What are the risks to revenue for NDC 71776-0100?
Risks include failure to demonstrate sufficient efficacy, safety concerns, regulatory delays, or market entry of competing therapies.
References
[1] IQVIA. (2022). Global Neurological Disorder Market Report.
[2] FDA. (2022). Orphan Drug Designation Program.
[3] IMS Health. (2022). Forecast for Amyotrophic Lateral Sclerosis (ALS) Treatments.
[4] NICE. (2022). Technology Appraisal Guidance for Neurodegenerative Treatments.
[5] Market Data Forecast. (2023). Neurodegenerative Disease Market Outlook.
